This showed that IL-1 blockers could have a high impact in the treatment of obesity-induced inflammation and insulin resistance as well as the treatment of autoimmune diseases, such as type 1 diabetes. The gene discussed is IL1B; the disease is obesity due to melanocortin 4 receptor deficiency.